19. EVALUATION FOR THE ANTIBACTERIAL AND ANTIFUNGAL ACTIVITIES IN VITRO AND IN SILICO OF SYNTHESIZED IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES
Main Article Content
Abstract
Objectives: Imidazole-4,5-dicarboxamide (I45DC) bearing the morpholine group has shown many diverse biological activities. The study aimed to further evaluate the antibacterial and antifungal activities of this group of compounds, using the in silico methods to interpret the results.
Methods: Method for testing antibacterial and antifungal activities in vitro: agar diffusion methods. Method for evaluating in silico antibacterial and antifungal activities include building 10 molecular docking models, evaluating the models using the redocking method, docking synthesized substances into 10 models and evaluating based on docking score. Pharmacokinetic and toxicological properties (ADMET) were evaluated using ADMETlab2.0 software.
Results: The synthesized substances did not show antibacterial or antifungal activities on the tested bacterial and fungal strains. In silico results showed that 10 substances were successfully docked to 10 common targets of bacteria and fungi. ADMET results showed some of the compounds are insoluble and cytotoxic.
Conclusions: The in silico results were not consistent with the in vitro results. This may be explained by the fact that the test substances may not form important interactions with the targets or due to poor solubility.
Article Details
Keywords
imidazole-4,5-dicarboxamide, antibacterial activity, antifungal activity
References
[2] Ozkay Y., Işikdağ I., Incesu Z., et al., (2010), Synthesis of 2-substituted-N-[4-(1-methyl-4,5-diphenyl-1H-imidazole-2-yl)phenyl]acetamide derivatives and evaluation of their anticancer activity. European journal of medicinal chemistry. 45(8), 3320-3328.
[3] Baures P.W., (1999), Heterocyclics HIV-1 protease inhibitors. Organic Letters. 1(2), 249-252.
[4] VanCompernolle S. E., Wiznycia A. V., Rush J. R., et al, (2004), Small molecule inhibition of hepatitis C virus E2 binding to CD81. Virology. 314(1), 371-380.
[5] Saudi M., Zmurko J., Kaptein S., et al, (2014) Synthesis and evaluation of imidazole-4,5-and pyrazine-2,3-dicarboxamide targeting dengue and yellow fever virus. European Journal of Medicinal Chemistry, 87, 529-539.
[6] Kourounakis A. P., Xanthopoulos D., Tzara A., (2019), Morpholine as a priviledged structure: A review on the medicinal chemistry and pharmacological activity of morpholine containing bioactive molecules. Med. Res. Rev. 1-44.
[7] -Vy P., Phuong N. H. H., Vu-Thuy-Vy N., et al, (2023), Discovery of a novel AcrAB-TolC pump inhibitor using the multistep virtual screening, synthesis and biological evaluation of asymmetric imidazole-4,5-dicarboxamide derivatives. New. J. Chem. 47, 20718-20722.
[8] Phuong N. H. H., Phatcharin K., Minh-Hoang P., et al, (2024), Asymmetric imidazole-4,5-dicarboxamide derivatives as SARS-CoV-2 main protease inhibitors: design, synthesis and biological evaluation. RSC. Med. Chem. Advanced article, DOI: 10.1039/D4MD00414K
[9] Phuong H. N. H., Phuc N. T., Phuong T., et al, (2024), Tổng hợp và đánh giá hoạt tính kháng khuẩn, kháng nấm các dẫn chất 2-methylimidazol-4,5-dicarboxamid bất đối xứng chứa morpholin. Sci. Tech. Dev. J. -Eng. Tech., 6(4), 2060-2072.
[10] Hoang M. P., Tan T. M., Thinh N. Q. Đ., et al, (2024), Synthesis and Evaluation of Antibacterial and Antifungal Activities In vitro and In silico of Novel Morpholinoalkoxychalcones. Med. Chem., in press, DOI: 10.2174/0115734064316 022240801093905